drugset / Trial / NCT03098550
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.
Timeline
- Start
- 2017-06-15
- Primary completion
- 2020-07-06
- Completion
- 2020-07-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |